


# Capture Hematology Imaging Biomarkers with Confidence



Hematology clinical trials are particularly complex, as they often require both imaging and a comprehensive review of clinical data, leading to very quick deliverable timeline expectations. Perceptive's operational strength and scientific knowledge meet the challenge head-on.

We have supported over 370 hematology studies across a wide range of indications including malignant and non-malignant conditions such as sickle cell disease. For hematologic malignancies, we have vast expertise across criteria, including:

► Lugano ► Lyric ► IMWG ► RECIL ► IWCLL ► IPNHLSS ► IWWM ► TMTV

## Why choose Perceptive Imaging

### Proven ability to deliver on tight timelines with uncompromised data quality

Success story: Delivered 1,200+ radiology and 1,500+ oncology reads for a multiple myeloma trial, achieving critical milestones on aggressive timelines. Breakthrough Therapy Designation granted and now FDA and EMA approved.

### Extensive experience in hematology trials with global regulatory approvals

Our team has supported over **370 malignant and non-malignant hematology trials**, contributing to **over 70 regulatory approvals** and **17 Breakthrough Therapy designations**.

### Broad KOL network featuring renowned advisors and internal experts


Perceptive's approach connects sponsors to a network of leading KOLs, including Bruce Cheson, MD, Shaji Kumar, MD, and Joseph Mikhael, MD, as well as our internal hematology experts.

### Expert protocol consultation

We design our approach to capture all essential imaging and clinical details from the start, supporting analysis, biomarkers, and efficacy endpoints with regulatory confidence.

### 24/7 support for seamless communication and issue resolution

Close collaboration with sponsors and globally positioned teams keeps trials moving forward, with rapid escalations ensuring efficient and successful outcomes.



# Hematology Experience

|                                                        | TRIALS IN HEMATOLOGY                     | TOTAL<br>370+ | APPROVALS<br>70+ |
|--------------------------------------------------------|------------------------------------------|---------------|------------------|
| MALIGNANT<br>HEMATOLOGY                                | Non-Hodgkins Lymphoma (NHL)              | 75+           | 15+              |
|                                                        | Follicular non-Hodgkin's Lymphoma (fNHL) | 40+           | 9                |
|                                                        | Diffuse Large B-Cell Lymphoma (DLBCL)    | 25+           | 6                |
|                                                        | Pediatric NHL                            | 4             | -                |
|                                                        | Chronic Lymphocytic Leukemia (CLL)       | 65+           | 15+              |
|                                                        | Multiple Myeloma                         | 45+           | 10+              |
|                                                        | Myelofibrosis                            | 40            | 8                |
|                                                        | Waldenstrom macroglobulinemia            | 8             | 7                |
|                                                        | Acute myeloid leukemia (AML)             | 3             | -                |
| BENIGN<br>HEMATOLOGY                                   | Sickle cell disease                      | 4             | 1                |
|                                                        | Beta-Thalassemia                         | 2             | -                |
| 17 HEMATOLOGY BREAKTHROUGH THERAPY APPROVALS SUPPORTED |                                          |               |                  |

**Note:**  
Additional  
hematology  
indications  
supported  
beyond those  
listed.

## Meet Our Hematology Experts

Meet Perceptive's internal hematology experts, whose deep clinical trial imaging expertise supports every phase of your hematology trial, from protocol design to regulatory success.



**Gregory Goldmacher, MD, PhD, MBA**  
Chief Scientific & Medical Officer



**Rohit Sood, MD, PhD**  
Scientific and Medical Services

## How can we help?

To learn more about partnering with Perceptive Imaging for clinical trial success, contact:

► [hello@perceptive.com](mailto:hello@perceptive.com)